Tryp Therapeutics Inc. (TRYPF)
- Previous Close
0.0470 - Open
0.0498 - Bid --
- Ask --
- Day's Range
0.0467 - 0.0498 - 52 Week Range
0.0041 - 0.0919 - Volume
399,838 - Avg. Volume
43,422 - Market Cap (intraday)
4.725M - Beta (5Y Monthly) -1.28
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0300 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Tryp Therapeutics Inc., a clinical-stage pharmaceutical development company, focuses on developing psilocybin-related molecules in Canada and the United States. Its lead program candidate TRP-8803, a proprietary formulation of IV-infused psilocin that completed Phase 2a clinical trial for the treatment of binge eating disorder, fibromyalgia, abdominal pain, and visceral tenderness. The company's program candidate TRP-8802, a synthetic and oral psilocybin for the treatment of binge eating, chronic pain, and other indications. The company was formerly known as Artos Pharma Corp. and changed its name to Tryp Therapeutics Inc. in June 2020. Tryp Therapeutics Inc. was incorporated in 2019 and is based in Kelowna, Canada.
www.tryptherapeutics.comRecent News: TRYPF
Performance Overview: TRYPF
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TRYPF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TRYPF
Valuation Measures
Market Cap
4.24M
Enterprise Value
6.39M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-1.58
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-140.38%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-4.79M
Diluted EPS (ttm)
-0.0300
Balance Sheet and Cash Flow
Total Cash (mrq)
2.06M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-1.8M
Company Insights: TRYPF
TRYPF does not have Company Insights